Sunandamedi

GLENMARK - Q1 RESULTS AND OBSERVATIONS

Long
NSE:GLENMARK   GLENMARK PHARM
Q1 2020, results
Financials Q1 FY2020-21 Q1 FY2019-20 % Change
Total Income ₹ 2403.30 crs ₹ 2324.54 crs Up Tick 3.39%
Net Profit ₹ 254.04 crs ₹ 109.28 crs Up Tick 132.47%
EPS ₹ 9 ₹ 3.87 Up Tick 132.56%.

THE FACTOR FOR 3% INCREASE IN TOP LINE IS NOT SO GOOD. BUT, THE PANDEMIC SITUATION SALES ARE GOOD. Q2 SHOULD BE FURTHER IMPROVED.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.